Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avandia Advisory Cmte. Is FDA's Primary Response To Congressional Pressure

Executive Summary

Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees

Related Content

Avandia Advisory Committee Re-Review Reflects Well On FDA
GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting
Broken RECORD: New Themes, Same Old Story for Avandia
FDA Oversight Of Clinical Trials Could Be Strengthened After Avandia Report
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
FDA Diabetes Guidance Encourages Enrollment Of Sicker Patients
Avandia Adds Black Box For Heart Attack Risk; Actos Launches Ads
Avandia Should Stay On Market With Warnings, Committee Says
FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts